Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush

Wedbush raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $14 from $13 and keeps an Outperform rating on the shares following quarterly results and updates regarding silevertinib clinical development. As a reminder, preliminary Phae 2 data for silever in NSCLC patients harboring uncommon EGFR mutations were reported in December. Wedbush looks forward to additional data readouts and expanding silevertinib development in the coming months.